Skip to main content
Fig. 2 | Cancers of the Head & Neck

Fig. 2

From: Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations

Fig. 2

Cetuximab-Mediated ADCC. The Fab portion of Cetuximab binds to EGFR on the surface of tumor cells, while its Fc region binds to the Fc receptor CD16/FcγRIII on the NK cell surface. This leads to NK cell activation and release of cytolytic granules containing perforin and granzyme B that result in tumor cell lysis and release of tumor antigen. This tumor antigen is subsequently presented on APCs to activate antigen-specific T-cells

Back to article page

Cancers of the Head & Neck

ISSN: 2059-7347

Contact us